#United States #New York #Class Action #Gross Law Firm #aTyr Pharma

aTyr Pharma Shareholders Alert

The Gross Law Firm has issued an important notice for investors of aTyr Pharma, Inc. (NASDAQ: ATYR) regarding a class action lawsuit. Shareholders who acquired shares during the specified time frame are encouraged to engage with the firm about potential participation as a lead plaintiff. Notably, being appointed as a lead plaintiff is not mandatory for involvement in any recovery from the case.

Key Information for Shareholders

• - Class Period: The lawsuit is pertinent to shares bought between November 7, 2024, and September 12, 2025.
• - Allegations: The complaint alleges that the defendants made excessively optimistic statements while simultaneously disseminating false and misleading information regarding the drug Efzofitimod. Specifically, concerns arose over the drug's ability to allow patients to completely reduce their steroid dosage. The truth surfaced during an investor call on September 15, 2025, when aTyr announced that its EFZO-FIT clinical trial did not meet its pivotal endpoints. It was revealed that the study did not achieve the expected primary endpoint related to mean daily corticosteroid doses at the 48-week mark.
• - Stock Decline: Following these revelations, shares of aTyr plummeted, dropping nearly 83.2% in a single day—falling from $6.03 on September 12, 2025, to $1.02 on September 15, 2025.

Upcoming Deadlines

• - Registration: The deadline for shareholders to register for this class action is December 8, 2025. It is imperative for interested parties to register promptly.
• - Next Steps: Once registered, participating shareholders will gain access to portfolio monitoring software, ensuring they receive updates throughout the lawsuit's lifecycle. Furthermore, there are no costs or obligations for participating in the case.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally for its commitment to safeguarding the interests of investors who have faced losses due to deceitful practices. The firm strives to hold companies accountable for misleading statements or information omissions that inflate stock prices artificially. Their mission revolves around ethical corporate behavior and protecting investor rights.

Contact Information

For those affected, the Gross Law Firm can be contacted at:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

In conclusion, if you are a shareholder of aTyr Pharma, Inc. who acquired shares during the class period, it is crucial to be aware of the developments surrounding this lawsuit. Engaging with legal counsel can help protect your investments during this critical time.